Dose escalation pharmacokinetics and lipid lowering activity of a novel farnesoid X receptor modulator: 16-Dehydropregnenolone

OBJECTIVES: To study the dose escalation pharmacokinetics and lipid lowering activity of a novel FXR modulator, 16-Dehydropregnenolone (DHP). MATERIALS AND METHODS: The disposition of DHP following oral (36, 72, 100 and 150 mg/kg) and intravenous (1, 5 and 10 mg/kg) administration and its dose-respo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Devendra, Khanna, Ashok K., Pratap, Ram, Sexana, Jitendra K., Bhatta, Rabi S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271541/
https://www.ncbi.nlm.nih.gov/pubmed/22345871
http://dx.doi.org/10.4103/0253-7613.91868

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3271541/
https://www.ncbi.nlm.nih.gov/pubmed/22345871
http://dx.doi.org/10.4103/0253-7613.91868

Ejemplares similares